Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9384243 | 0.72 | PARP1 (0.44) | ADORA2AADORA1PARP1AURKAFEN1 | |
| SCHEMBL5216 | 0.71 | — | — | |
| SCHEMBL30421286 | 0.71 | AXL (0.53) | ADORA2AADORA1PARP1AURKAFEN1 | |
| SCHEMBL1566406 | 0.71 | AXL (0.53) | ADORA2AADORA1PARP1AURKAFEN1 | |
| Hydrochloric Acid SCHEMBL29744480 | 0.69 | AXL (0.52) | ADORA2AADORA1PARP1AURKAFEN1 | |
| SCHEMBL3768493 | 0.69 | ADORA2A (0.46) | ADORA2AADORA1PARP1AURKAFEN1 | |
| SCHEMBL30266660 | 0.68 | ADORA2A (0.45) | ADORA2AADORA1PARP1AURKAFEN1 | |
| SCHEMBL223036 | 0.67 | GAA (0.44) | PARP1FEN1KMT2ACDK4CCND1 | |
| SCHEMBL4343732 | 0.67 | ADORA2A (0.59) | ADORA2AADORA1PARP1AURKAFEN1 | |
| SCHEMBL9694560 | 0.67 | ADORA1 (0.59) | ADORA2AADORA1PARP1AURKAFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856747-B1 | SUBSTITUTED PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-07-19 | — | — | EP | claimed |
| EP-3856747-A1 | SUBSTITUTED PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-08-04 | — | — | EP | claimed |
| US-20210221832-A1 | SUBSTITUTED PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-07-22 | — | — | US | claimed |
| CN-112752762-A | Substituted pyridoindoles for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2021-05-04 | — | — | CN | claimed |
| WO-2020064661-A1 | SUBSTITUTED PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-02 | — | — | WO | claimed |
| US-9126979-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | claimed |
| US-9126980-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | claimed |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2015-03-19 | — | — | US | claimed |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | claimed |
| US-20140357633-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-12-04 | — | — | US | claimed |
| EP-2794591-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| EP-2794590-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| EP-2794592-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| EP-2794588-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| WO-2013096049-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | claimed |
| WO-2013096051-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | claimed |
| WO-2013096060-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | claimed |
| WO-2013096059-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | claimed |
| WO-2013096055-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | claimed |
| US-20030109705-A1 | Novel cyanoenamines useful as ligands for modulating gene expression in plants or animals | SYNGENTA PARTICIPATIONS AG (CH) | 2003-06-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357633-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | ADORA2A 3227/4885ADORA1 3887/4885PARP1 384/4885 |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | ADORA2A 3227/4885ADORA1 3887/4885PARP1 384/4885 |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | ADORA2A 3214/4885ADORA1 4013/4885PARP1 490/4885 |
| US-20030109705-A1 | Novel cyanoenamines useful as ligands for modulating gene expression in plants or animals | ACSL1, ACVRL1, DCLK3 | ADORA2A 2028/4885ADORA1 948/4885PARP1 3747/4885 |
| US-20210221832-A1 | SUBSTITUTED PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | BLVRB, PNPO, IL17A | ADORA2A 1269/4885ADORA1 130/4885PARP1 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.